New combo therapy targets Hard-to-Treat lymphoma
Disease control
Recruiting now
This study is for adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. Researchers are testing a drug called loncastuximab tesirine combined with other anti-cancer drugs to find the safest dose and see if it shrinks tumors. About 200 part…
Phase: PHASE1 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC